{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "15",
                "@timestamp": "2023-08-15T07:50:19.000019-04:00",
                "@year": "2023",
                "@month": "08"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2023",
                "@month": "01"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": {
                "xocs:funding-agency-matched-string": "Novavax, Inc.",
                "xocs:funding-agency": "Novavax",
                "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100014101",
                "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
            },
            "xocs:funding-addon-generated-timestamp": "2023-07-14T23:11:58.401Z",
            "xocs:funding-text": "This paper was funded by Novavax, Inc.",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60138508",
                            "@country": "usa",
                            "city": "Gaithersburg",
                            "organization": [
                                {"$": "Medical Affairs"},
                                {"$": "Novavax Inc"}
                            ],
                            "affiliation-id": {"@afid": "60138508"},
                            "state": "MD",
                            "@affiliation-instance-id": "OB2BibRecID-949395379-ef3e2272e351cd37ee9e4f6569d86afd-1",
                            "ce:source-text": "Medical Affairs, Novavax Inc, Gaithersburg, Maryland, USA"
                        },
                        "author": [
                            {
                                "ce:given-name": "Anthony M.",
                                "preferred-name": {
                                    "ce:given-name": "Anthony M.",
                                    "ce:initials": "A.M.",
                                    "ce:surname": "Marchese",
                                    "ce:indexed-name": "Marchese A.M."
                                },
                                "@author-instance-id": "OB2BibRecID-949395379-aaada7a2cd120ba1cf9b6610adadd85d-1",
                                "@seq": "1",
                                "ce:initials": "A.M.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Marchese",
                                "@auid": "57925281800",
                                "ce:indexed-name": "Marchese A.M."
                            },
                            {
                                "ce:given-name": "Seth",
                                "preferred-name": {
                                    "ce:given-name": "Seth",
                                    "ce:initials": "S.",
                                    "ce:surname": "Toback",
                                    "ce:indexed-name": "Toback S."
                                },
                                "@author-instance-id": "OB2BibRecID-949395379-827c83bafbb7493000c0c9d706fc836d-1",
                                "@seq": "5",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Toback",
                                "@auid": "14032330900",
                                "ce:indexed-name": "Toback S."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Center of Excellence in Clinical Virology"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "105867240"
                                },
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-949395379-33d4771fca98fe6db77dff9c49dbd67d-1",
                            "ce:source-text": "Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand",
                            "@dptid": "105867240"
                        },
                        "author": [
                            {
                                "ce:given-name": "Nungruthai",
                                "preferred-name": {
                                    "ce:given-name": "Nungruthai",
                                    "ce:initials": "N.",
                                    "ce:surname": "Suntronwong",
                                    "ce:indexed-name": "Suntronwong N."
                                },
                                "@author-instance-id": "OB2BibRecID-949395379-64300313b36af4d87654e56afb4d310e-1",
                                "@seq": "4",
                                "ce:initials": "N.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Suntronwong",
                                "@auid": "57189067135",
                                "ce:indexed-name": "Suntronwong N."
                            },
                            {
                                "ce:given-name": "Yong",
                                "preferred-name": {
                                    "ce:given-name": "Yong",
                                    "ce:initials": "Y.",
                                    "ce:surname": "Poovorawan",
                                    "ce:indexed-name": "Poovorawan Y."
                                },
                                "@author-instance-id": "OB2BibRecID-949395379-afeb3173fe6efbc4c7b59d3ce4f49973-1",
                                "@seq": "6",
                                "ce:initials": "Y.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Poovorawan",
                                "@auid": "7102786191",
                                "ce:indexed-name": "Poovorawan Y."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60138508",
                            "@country": "usa",
                            "city": "Gaithersburg",
                            "organization": [
                                {"$": "Clinical Immunology"},
                                {"$": "Novavax Inc"}
                            ],
                            "affiliation-id": {
                                "@afid": "60138508",
                                "@dptid": "129170218"
                            },
                            "state": "MD",
                            "@affiliation-instance-id": "OB2BibRecID-949395379-bdf80994206de60698fc78db77475cc9-1",
                            "ce:source-text": "Clinical Immunology, Novavax Inc, Gaithersburg, Maryland",
                            "@dptid": "129170218"
                        },
                        "author": [{
                            "ce:given-name": "Raj",
                            "preferred-name": {
                                "ce:given-name": "Raj",
                                "ce:initials": "R.",
                                "ce:surname": "Kalkeri",
                                "ce:indexed-name": "Kalkeri R."
                            },
                            "@author-instance-id": "OB2BibRecID-949395379-5e0f505db356095fd4baecfa7c7d6ffb-1",
                            "@seq": "2",
                            "ce:initials": "R.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Kalkeri",
                            "@auid": "57191375845",
                            "ce:indexed-name": "Kalkeri R."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60138508",
                            "@country": "usa",
                            "city": "Gaithersburg",
                            "organization": [
                                {"$": "Medical Affairs (APAC Region)"},
                                {"$": "Novavax Inc"}
                            ],
                            "affiliation-id": {"@afid": "60138508"},
                            "state": "MD",
                            "@affiliation-instance-id": "OB2BibRecID-949395379-7bd147c6e5948c8538ba524e8e4aa411-1",
                            "ce:source-text": "Medical Affairs (APAC Region), Novavax Inc, Gaithersburg, Maryland, USA"
                        },
                        "author": [{
                            "ce:given-name": "Muruga",
                            "preferred-name": {
                                "ce:given-name": "Muruga",
                                "ce:initials": "M.",
                                "ce:surname": "Vadivale",
                                "ce:indexed-name": "Vadivale M."
                            },
                            "@author-instance-id": "OB2BibRecID-949395379-45f237963883825f556836703622bba0-1",
                            "@seq": "3",
                            "ce:initials": "M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Vadivale",
                            "@auid": "6507179068",
                            "ce:indexed-name": "Vadivale M."
                        }]
                    }
                ],
                "citation-title": "Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines",
                "abstracts": "© 2023 Novavax Inc. Published by Informa UK Limited, trading as Taylor & Francis Group.Introduction: Approximately half of the 13.4 billion COVID-19 vaccine doses administered globally were inactivated or viral vector platforms. The harmonization and optimization of vaccine regimens has become a key focus of policymakers and health-care providers and presents an opportunity to reassess the continued use of pandemic-era vaccines. Areas covered: Immunological evidence from studies of various homologous and heterologous regimens has been rapidly published; however, interpretation of these data is complicated by the many vaccine types and highly variable participant viral exposure and vaccination histories. Recent studies demonstrate that after primary series doses of inactivated (i.e. BBV152, and BBIBP-CorV), and viral vector (ChAdOx1 nCov-2019) vaccines, a heterologous boost with protein-based NVX-CoV2373 elicits more potent ancestral strain and omicron-specific antibody responses compared to homologous and heterologous inactivated and viral vector boosts. Expert opinion: While mRNA vaccines likely yield similar performance to protein-based heterologous booster doses, the latter offers notable advantages to countries with high uptake of inactivated and viral vector vaccines in terms of transportation and storage logistics and can potentially appeal to vaccine hesitant individuals. Moving forward, vaccine-mediated protection in inactivated and viral vector recipients may be optimized with the use of a heterologous protein-based booster such as NVX-CoV2373. Pivoting to Protein: The Immunogenicity and Safety of Protein-based NVX-CoV2373 as a Heterologous Booster for Inactivated and Viral Vector COVID-19 Vaccines. Inactivated or viral vector primary series following a booster dose with homologous or heterologous inactivated vaccines (i.e., BBV152, BBIBP-CorV), and homologous or heterologous viral vector vaccines (i.e., ChAd-Ox1 nCov-19) induces suboptimal immunogenicity compared to the enhanced immunogenicity of heterologous protein-based vaccine NVX-CoV2373.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "address-part": "21 Firstfield Rd",
                        "postal-code": "20878",
                        "@country": "usa",
                        "city": "Gaithersburg",
                        "organization": {"$": "Novavax Inc"},
                        "state": "MD",
                        "@affiliation-instance-id": "OB2BibRecID-949395379-8a3b36d99c744a96d0216a287dd08f4b-1",
                        "ce:source-text": "Novavax Inc, 21 Firstfield Rd, Gaithersburg, Maryland, 20878, USA"
                    },
                    "person": {
                        "ce:given-name": "Anthony M.",
                        "@author-instance-id": "OB2BibRecID-949395379-458c592856ee5e9204b336e55c852018-1",
                        "ce:initials": "A.M.",
                        "ce:surname": "Marchese",
                        "ce:indexed-name": "Marchese A.M."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "COVID-19 vaccines",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "heterologous booster",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "inactivated",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "NVX-CoV2373",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "protein-based",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "viral vector",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "no"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "http://www.tandfonline.com/loi/ierv20",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Expert Review of Vaccines",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "22",
                            "@issue": "1"
                        },
                        "pagerange": {
                            "@first": "620",
                            "@last": "628"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "Expert Review of Vaccines",
                    "publicationdate": {
                        "year": "2023",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "2023"
                        }
                    },
                    "codencode": "ERVXA",
                    "sourcetitle-abbrev": "Expert Rev. Vaccines",
                    "@country": "gbr",
                    "issn": [
                        {
                            "$": "17448395",
                            "@type": "electronic"
                        },
                        {
                            "$": "14760584",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2023"},
                    "publisher": {"publishername": "Taylor and Francis Ltd."},
                    "@srcid": "20783"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "26",
                                    "classification-description": "Immunology, Serology and Transplantation"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                },
                                {
                                    "classification-code": "38",
                                    "classification-description": "Adverse Reactions Titles"
                                },
                                {
                                    "classification-code": "4",
                                    "classification-description": "Microbiology: Bacteriology, Mycology, Parasitology and Virology"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": [
                                {"$": "2403"},
                                {"$": "1313"},
                                {"$": "3004"},
                                {"$": "3002"}
                            ]
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": [
                                {"$": "IMMU"},
                                {"$": "BIOC"},
                                {"$": "PHAR"}
                            ]
                        }
                    ]},
                    "tradenamegroup": {"tradenames": {
                        "trademanuitem": [
                            {
                                "tradename": "ad 26cov 2s",
                                "manufacturer": "Janssen"
                            },
                            {"tradename": "bbibp corv"},
                            {
                                "tradename": "bbv 152",
                                "manufacturer": {
                                    "@country": "ind",
                                    "$": "Bharat Biotech"
                                }
                            },
                            {
                                "tradename": "corbevax",
                                "manufacturer": "texas childrens hospital"
                            },
                            {
                                "tradename": "coronavac",
                                "manufacturer": {
                                    "@country": "chn",
                                    "$": "Sinovac"
                                }
                            },
                            {
                                "tradename": "corvilo",
                                "manufacturer": {
                                    "@country": "chn",
                                    "$": "Sinopharm"
                                }
                            },
                            {"tradename": "covaxin"},
                            {
                                "tradename": "covishield",
                                "manufacturer": "Astra Zeneca"
                            },
                            {
                                "tradename": "covovax",
                                "manufacturer": {
                                    "@country": "usa",
                                    "$": "Novavax"
                                }
                            },
                            {
                                "tradename": "indovac",
                                "manufacturer": "pt bio farma and baylor college of medicine"
                            },
                            {
                                "tradename": "jcovden",
                                "manufacturer": "Dynavax"
                            },
                            {
                                "tradename": "mvc cov 1901",
                                "manufacturer": "medigen vaccine biologics"
                            },
                            {
                                "tradename": "nuvaxovid",
                                "manufacturer": {
                                    "@country": "usa",
                                    "$": "Novavax"
                                }
                            },
                            {"tradename": "nvx cov 2373"},
                            {
                                "tradename": "nvx cov 2373",
                                "manufacturer": {
                                    "@country": "jpn",
                                    "$": "takeda pharmaceutical company"
                                }
                            },
                            {"tradename": "sii nvx cov 2373"},
                            {
                                "tradename": "tak 019",
                                "manufacturer": {
                                    "@country": "usa",
                                    "$": "Novavax"
                                }
                            },
                            {
                                "tradename": "vaxzevria",
                                "manufacturer": {
                                    "@country": "gbr",
                                    "$": "Astra Zeneca"
                                }
                            },
                            {
                                "tradename": "vidprevtyn beta",
                                "manufacturer": "Labaz"
                            },
                            {
                                "tradename": "vla 2001",
                                "manufacturer": "Valneva"
                            },
                            {
                                "tradename": "zf 2001",
                                "manufacturer": "Anhui Zhifei Longcom"
                            },
                            {
                                "tradename": "zifivax",
                                "manufacturer": {
                                    "@country": "chn",
                                    "$": "Anhui Zhifei Longcom"
                                }
                            }
                        ],
                        "@type": "TNM"
                    }},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": "2541607-46-7",
                                    "chemical-name": "ibacovavec"
                                },
                                {
                                    "cas-registry-number": "2420395-83-9",
                                    "chemical-name": "vaxzevria"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Antibodies, Viral"},
                                {"chemical-name": "BBV152 COVID-19 vaccine"},
                                {"chemical-name": "BIBP COVID-19 vaccine"},
                                {"chemical-name": "COVID-19 Vaccines"},
                                {"chemical-name": "NVX-CoV2373 adjuvated lipid nanoparticle"},
                                {"chemical-name": "Vaccines, Inactivated"},
                                {"chemical-name": "Viral Vaccines"}
                            ]
                        }
                    ]},
                    "manufacturergroup": {"manufacturers": {
                        "@type": "MNF",
                        "manufacturer": [
                            {"$": "Anhui Zhifei Longcom"},
                            {"$": {
                                "@country": "chn",
                                "$": "Anhui Zhifei Longcom"
                            }},
                            {"$": "Astra Zeneca"},
                            {
                                "@country": "gbr",
                                "$": "Astra Zeneca"
                            },
                            {
                                "@country": "ind",
                                "$": "Bharat Biotech"
                            },
                            {"$": "Dynavax"},
                            {"$": "Glaxo SmithKline"},
                            {"$": "Janssen"},
                            {"$": "Johnson and Johnson"},
                            {"$": "Labaz"},
                            {"$": "medigen vaccine biologics"},
                            {"$": "pt bio farma and baylor college of medicine"},
                            {
                                "@country": "chn",
                                "$": "Sinopharm"
                            },
                            {
                                "@country": "chn",
                                "$": "Sinovac"
                            },
                            {
                                "@country": "ind",
                                "$": "Serum Institute of India"
                            },
                            {
                                "@country": "jpn",
                                "$": "takeda pharmaceutical company"
                            },
                            {
                                "@country": "usa",
                                "$": "Novavax"
                            },
                            {"$": "texas childrens hospital"},
                            {"$": "Valneva"}
                        ]
                    }}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "This paper was funded by Novavax, Inc.",
                        "@xml:lang": "eng"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2023 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "11",
                    "@timestamp": "BST 03:27:56",
                    "@year": "2023",
                    "@month": "08"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2024287866",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "641716130",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "949395379",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20230650479",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "37386785",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20231966687",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20232589891",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20239022206843",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85164270417",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85164270417",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "641716130",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "78110699",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1080/14760584.2023.2232020"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "63",
                "reference": [
                    {
                        "ref-fulltext": "Our World in Data. Coronavirus (COVID-19) vaccinations: global change data lab [cited 2023 May8]. Available from: https://ourworldindata.org/covid-vaccinations",
                        "@reference-instance-id": "OB2BibRecID-949395379-7b198ab62013bf8b72dbc325a19b7aaf-1",
                        "@id": "1",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://ourworldindata.org/covid-vaccinations",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0001",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85083069159",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "[cited 2023 May8]. Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Our World in Data",
                                "ce:indexed-name": "Our World in Data"
                            }},
                            "ref-sourcetitle": "Coronavirus (COVID-19) vaccinations: global change data lab"
                        },
                        "ce:source-text": "Our World in Data. Coronavirus (COVID-19) vaccinations: global change data lab [cited 2023 May8]. Available from: https://ourworldindata.org/covid-vaccinations"
                    },
                    {
                        "ref-fulltext": "COVID-19 Vaccination Pharmaceutical Technology [updated 2023 Apr13; cited 2023 Apr27]. Available from: https://www.pharmaceutical-technology.com/covid-19-vaccination-tracker/",
                        "@reference-instance-id": "OB2BibRecID-949395379-3e7f15cd95a105bf0c4d53feca340b9f-2",
                        "@id": "2",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.pharmaceutical-technology.com/covid-19-vaccination-tracker/",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0002",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164515919",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "[updated 2023 Apr13, cited 2023 Apr27], Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "COVID-19 Vaccination Pharmaceutical Technology",
                                "ce:indexed-name": "COVID-19 Vaccination Pharmaceutical Technology"
                            }}
                        },
                        "ce:source-text": "COVID-19 Vaccination Pharmaceutical Technology [updated 2023 Apr13; cited 2023 Apr27]. Available from: https://www.pharmaceutical-technology.com/covid-19-vaccination-tracker/"
                    },
                    {
                        "ref-fulltext": "Sanders B, Koldijk M, Schuitemaker H. Inactivated viral vaccines. Vaccine analysis: strategies, principles, and control. 2014; 45\u201380.",
                        "@reference-instance-id": "OB2BibRecID-949395379-3a6de9c39d2346eb1c65428565e07fad-3",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Inactivated viral vaccines"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0003",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84943632063",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"pagerange": {
                                "@first": "45",
                                "@last": "80"
                            }},
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Sanders",
                                    "ce:indexed-name": "Sanders B."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Koldijk",
                                    "ce:indexed-name": "Koldijk M."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Schuitemaker",
                                    "ce:indexed-name": "Schuitemaker H."
                                }
                            ]},
                            "ref-sourcetitle": "Vaccine analysis: strategies, principles, and control"
                        },
                        "ce:source-text": "Sanders B, Koldijk M, Schuitemaker H. Inactivated viral vaccines. Vaccine analysis: strategies, principles, and control. 2014; 45\u201380."
                    },
                    {
                        "ref-fulltext": "Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013; 4: 114. doi: 10.3389/fimmu.2013.00114",
                        "@reference-instance-id": "OB2BibRecID-949395379-34ff8448848dd9a48beac7b844d4c659-4",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Mechanisms of action of adjuvants"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.3389/fimmu.2013.00114",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0004",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84883817330",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {"@first": "114"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Awate",
                                    "ce:indexed-name": "Awate S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "L.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Babiuk",
                                    "ce:indexed-name": "Babiuk L.A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "G.",
                                    "@_fa": "true",
                                    "ce:surname": "Mutwiri",
                                    "ce:indexed-name": "Mutwiri G."
                                }
                            ]},
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013; 4: 114. doi: 10.3389/fimmu.2013.00114"
                    },
                    {
                        "ref-fulltext": "Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021 Dec 11; 398 (10317): 2173\u20132184.",
                        "@reference-instance-id": "OB2BibRecID-949395379-dd1fb7566b7287ba3e565b50eb6bb216-5",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0005",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85120741950",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "398"},
                                "pagerange": {
                                    "@first": "2173",
                                    "@last": "2184"
                                }
                            },
                            "ref-text": "Dec, 11, 10317",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Ella",
                                        "ce:indexed-name": "Ella R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Reddy",
                                        "ce:indexed-name": "Reddy S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Blackwelder",
                                        "ce:indexed-name": "Blackwelder W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021 Dec 11; 398 (10317): 2173\u20132184."
                    },
                    {
                        "ref-fulltext": "Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021 Jul 6; 326 (1): 35\u201345.",
                        "@reference-instance-id": "OB2BibRecID-949395379-447cf7080cfa53d38f10cb071391bf5c-6",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0006",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85106884010",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "326",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "35",
                                    "@last": "45"
                                }
                            },
                            "ref-text": "Jul, 6",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Al Kaabi",
                                        "ce:indexed-name": "Al Kaabi N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Xia",
                                        "ce:indexed-name": "Xia S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA"
                        },
                        "ce:source-text": "Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021 Jul 6; 326 (1): 35\u201345."
                    },
                    {
                        "ref-fulltext": "Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17; 398 (10296): 213\u2013222.",
                        "@reference-instance-id": "OB2BibRecID-949395379-04bed2d8b85e209814842a668fba692e-7",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0007",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85110110235",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "398"},
                                "pagerange": {
                                    "@first": "213",
                                    "@last": "222"
                                }
                            },
                            "ref-text": "Jul, 17, 10296",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Tanriover",
                                        "ce:indexed-name": "Tanriover M.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Doganay",
                                        "ce:indexed-name": "Doganay H.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Akova",
                                        "ce:indexed-name": "Akova M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17; 398 (10296): 213\u2013222."
                    },
                    {
                        "ref-fulltext": "COVID-19 Vaccine Tracker [updated 2023 Mar4; cited 2023 Apr27]. Available from: https://covid19.trackvaccines.org/vaccines/#progress-meter",
                        "@reference-instance-id": "OB2BibRecID-949395379-767a38948b7cb3c230457c97b818ab74-8",
                        "@id": "8",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://covid19.trackvaccines.org/vaccines/#progress-meter",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0008",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164463066",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "[updated 2023 Mar4, cited 2023 Apr27], Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "COVID-19 Vaccine Tracker",
                                "ce:indexed-name": "COVID-19 Vaccine Tracker"
                            }}
                        },
                        "ce:source-text": "COVID-19 Vaccine Tracker [updated 2023 Mar4; cited 2023 Apr27]. Available from: https://covid19.trackvaccines.org/vaccines/#progress-meter"
                    },
                    {
                        "ref-fulltext": "Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022 Feb 10; 386 (6): 531\u2013543.",
                        "@reference-instance-id": "OB2BibRecID-949395379-4ba74cff3fcc423a3615e2a82634c979-9",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0009",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85123980637",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "386",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "531",
                                    "@last": "543"
                                }
                            },
                            "ref-text": "Feb, 10",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Dunkle",
                                        "ce:indexed-name": "Dunkle L.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Kotloff",
                                        "ce:indexed-name": "Kotloff K.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Gay",
                                        "ce:indexed-name": "Gay C.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022 Feb 10; 386 (6): 531\u2013543."
                    },
                    {
                        "ref-fulltext": "Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-Dimer-based Covid-19 vaccine ZF2001 in adults. N Engl J Med. 2022 Jun 2; 386 (22): 2097\u20132111.",
                        "@reference-instance-id": "OB2BibRecID-949395379-616541ab524b3d6d9338307772d8a483-10",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of the RBD-Dimer-based Covid-19 vaccine ZF2001 in adults"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0010",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85130329652",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "386",
                                    "@issue": "22"
                                },
                                "pagerange": {
                                    "@first": "2097",
                                    "@last": "2111"
                                }
                            },
                            "ref-text": "Jun, 2",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Dai",
                                        "ce:indexed-name": "Dai L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Gao",
                                        "ce:indexed-name": "Gao L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Tao",
                                        "ce:indexed-name": "Tao L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-Dimer-based Covid-19 vaccine ZF2001 in adults. N Engl J Med. 2022 Jun 2; 386 (22): 2097\u20132111."
                    },
                    {
                        "ref-fulltext": "Marchese AM, Zhou X, Kinol J, et al. NVX-Cov2373 vaccine efficacy against hospitalization: a post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial. medRxiv. 2023. Preprint. doi: 10.1101/2023.03.17.23287306.",
                        "@reference-instance-id": "OB2BibRecID-949395379-4441a4f82f6acb6c0d707b96c57c145f-11",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "NVX-Cov2373 vaccine efficacy against hospitalization: a post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1101/2023.03.17.23287306",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0011",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85162975840",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Preprint",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Marchese",
                                        "ce:indexed-name": "Marchese A.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhou",
                                        "ce:indexed-name": "Zhou X."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Kinol",
                                        "ce:indexed-name": "Kinol J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "medRxiv"
                        },
                        "ce:source-text": "Marchese AM, Zhou X, Kinol J, et al. NVX-Cov2373 vaccine efficacy against hospitalization: a post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial. medRxiv. 2023. Preprint. doi: 10.1101/2023.03.17.23287306."
                    },
                    {
                        "ref-fulltext": "Torales J, Cuenca-Torres O, Barrios L, et al. An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled study. medRxiv. 2022. Preprint. doi: 10.1101/2022.07.14.22277617.",
                        "@reference-instance-id": "OB2BibRecID-949395379-0a3fa520a441d3ef5f0c2e50e1686f81-12",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1101/2022.07.14.22277617",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0012",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164531538",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Preprint",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Torales",
                                        "ce:indexed-name": "Torales J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "O.",
                                        "@_fa": "true",
                                        "ce:surname": "Cuenca-Torres",
                                        "ce:indexed-name": "Cuenca-Torres O."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Barrios",
                                        "ce:indexed-name": "Barrios L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "medRxiv"
                        },
                        "ce:source-text": "Torales J, Cuenca-Torres O, Barrios L, et al. An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled study. medRxiv. 2022. Preprint. doi: 10.1101/2022.07.14.22277617."
                    },
                    {
                        "ref-fulltext": "ClinicalTrials.gov. Immuno-bridging study of COVID-19 protein subunit recombinant vaccine (NCT05433285) [cited 2023 Apr27]. Available from: https://clinicaltrials.gov/ct2/show/NCT05433285",
                        "@reference-instance-id": "OB2BibRecID-949395379-2eed54f3b5bb8b836c8e93cdba486fd5-13",
                        "@id": "13",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://clinicaltrials.gov/ct2/show/NCT05433285",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0013",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164526651",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "[cited 2023 Apr27]. Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "ClinicalTrials.gov",
                                "ce:indexed-name": "ClinicalTrials.gov"
                            }},
                            "ref-sourcetitle": "Immuno-bridging study of COVID-19 protein subunit recombinant vaccine (NCT05433285)"
                        },
                        "ce:source-text": "ClinicalTrials.gov. Immuno-bridging study of COVID-19 protein subunit recombinant vaccine (NCT05433285) [cited 2023 Apr27]. Available from: https://clinicaltrials.gov/ct2/show/NCT05433285"
                    },
                    {
                        "ref-fulltext": "Lazarus R, Querton B, Corbic Ramljak I, et al. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect Dis. 2022 Dec; 22 (12): 1716\u20131727.",
                        "@reference-instance-id": "OB2BibRecID-949395379-a40410c01744b7b99266c63e27ed8c61-14",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0014",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85140082654",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "22",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1716",
                                    "@last": "1727"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Lazarus",
                                        "ce:indexed-name": "Lazarus R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Querton",
                                        "ce:indexed-name": "Querton B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Corbic Ramljak",
                                        "ce:indexed-name": "Corbic Ramljak I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Infect Dis"
                        },
                        "ce:source-text": "Lazarus R, Querton B, Corbic Ramljak I, et al. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect Dis. 2022 Dec; 22 (12): 1716\u20131727."
                    },
                    {
                        "ref-fulltext": "Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose ad26.COV2.S vaccine against covid-19. N Engl J Med. 2021 Jun 10; 384 (23): 2187\u20132201.",
                        "@reference-instance-id": "OB2BibRecID-949395379-d0907554d6da5a7fb2d0b579942bad56-15",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Safety and efficacy of single-dose ad26.COV2.S vaccine against covid-19"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0015",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85105119482",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "384",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "2187",
                                    "@last": "2201"
                                }
                            },
                            "ref-text": "Jun, 10",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Sadoff",
                                        "ce:indexed-name": "Sadoff J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Gray",
                                        "ce:indexed-name": "Gray G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Vandebosch",
                                        "ce:indexed-name": "Vandebosch A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose ad26.COV2.S vaccine against covid-19. N Engl J Med. 2021 Jun 10; 384 (23): 2187\u20132201."
                    },
                    {
                        "ref-fulltext": "Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9; 397 (10269): 99\u2013111.",
                        "@reference-instance-id": "OB2BibRecID-949395379-e0810e9ca2c5ae030a3b5220dfa31191-16",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0016",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85097463811",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "397"},
                                "pagerange": {
                                    "@first": "99",
                                    "@last": "111"
                                }
                            },
                            "ref-text": "Jan, 9, 10269",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Voysey",
                                        "ce:indexed-name": "Voysey M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Clemens",
                                        "ce:indexed-name": "Clemens S.A.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Madhi",
                                        "ce:indexed-name": "Madhi S.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9; 397 (10269): 99\u2013111."
                    },
                    {
                        "ref-fulltext": "Vetter V, Denizer G, Friedland LR, et al. Understanding modern-day vaccines: what you need to know. Ann Med. 2018 Mar; 50 (2): 110\u2013120.",
                        "@reference-instance-id": "OB2BibRecID-949395379-e42150286406babbe610368c575c4ea9-17",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Understanding modern-day vaccines: what you need to know"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0017",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85035109146",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "50",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "110",
                                    "@last": "120"
                                }
                            },
                            "ref-text": "Mar",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Vetter",
                                        "ce:indexed-name": "Vetter V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Denizer",
                                        "ce:indexed-name": "Denizer G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Friedland",
                                        "ce:indexed-name": "Friedland L.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Med"
                        },
                        "ce:source-text": "Vetter V, Denizer G, Friedland LR, et al. Understanding modern-day vaccines: what you need to know. Ann Med. 2018 Mar; 50 (2): 110\u2013120."
                    },
                    {
                        "ref-fulltext": "Chang J. Adenovirus vectors: excellent tools for vaccine development. Immune Netw. 2021 Feb; 21 (1): e6. doi: 10.4110/in.2021.21.e6",
                        "@reference-instance-id": "OB2BibRecID-949395379-96f9e931975ebd3a6d88ecdf4cf32543-18",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Adenovirus vectors: excellent tools for vaccine development"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.4110/in.2021.21.e6",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0018",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85102753439",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "21",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "e6"}
                            },
                            "ref-text": "Feb",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "J.",
                                "@_fa": "true",
                                "ce:surname": "Chang",
                                "ce:indexed-name": "Chang J."
                            }]},
                            "ref-sourcetitle": "Immune Netw"
                        },
                        "ce:source-text": "Chang J. Adenovirus vectors: excellent tools for vaccine development. Immune Netw. 2021 Feb; 21 (1): e6. doi: 10.4110/in.2021.21.e6"
                    },
                    {
                        "ref-fulltext": "Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells. 2008 Jun 30; 25 (4): 462\u2013466.",
                        "@reference-instance-id": "OB2BibRecID-949395379-508d312ed0f1abe7418db0183440c5ac-19",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-title": {"ref-titletext": "The current status of adenovirus-based cancer gene therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0019",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "57349167467",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "462",
                                    "@last": "466"
                                }
                            },
                            "ref-text": "Jun, 30",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "T.",
                                "@_fa": "true",
                                "ce:surname": "Shirakawa",
                                "ce:indexed-name": "Shirakawa T."
                            }]},
                            "ref-sourcetitle": "Mol Cells"
                        },
                        "ce:source-text": "Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells. 2008 Jun 30; 25 (4): 462\u2013466."
                    },
                    {
                        "ref-fulltext": "Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol. 2007 May; 36 (1): 71\u201380. doi: 10.1007/s12033-007-0021-5",
                        "@reference-instance-id": "OB2BibRecID-949395379-4310940eeed9e12c6b8a9713dbb42ac3-20",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-title": {"ref-titletext": "Adenoviral vectors for gene therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1007/s12033-007-0021-5",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0020",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "34848904829",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "71",
                                    "@last": "80"
                                }
                            },
                            "ref-text": "May",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "J.T.",
                                "@_fa": "true",
                                "ce:surname": "Douglas",
                                "ce:indexed-name": "Douglas J.T."
                            }]},
                            "ref-sourcetitle": "Mol Biotechnol"
                        },
                        "ce:source-text": "Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol. 2007 May; 36 (1): 71\u201380. doi: 10.1007/s12033-007-0021-5"
                    },
                    {
                        "ref-fulltext": "Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther. 2007 Jun; 7 (3): 189\u2013204. doi: 10.2174/156652307780859062",
                        "@reference-instance-id": "OB2BibRecID-949395379-ee9a4bd47d2533bca179bd3b6e868c0c-21",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-title": {"ref-titletext": "Current advances and future challenges in Adenoviral vector biology and targeting"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.2174/156652307780859062",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0021",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "34250191828",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "189",
                                    "@last": "204"
                                }
                            },
                            "ref-text": "Jun",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.K.",
                                    "@_fa": "true",
                                    "ce:surname": "Campos",
                                    "ce:indexed-name": "Campos S.K."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Barry",
                                    "ce:indexed-name": "Barry M.A."
                                }
                            ]},
                            "ref-sourcetitle": "Curr Gene Ther"
                        },
                        "ce:source-text": "Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther. 2007 Jun; 7 (3): 189\u2013204. doi: 10.2174/156652307780859062"
                    },
                    {
                        "ref-fulltext": "Goncalves MA, de Vries AA. Adenovirus: from foe to friend. Rev Med Virol. 2006 May; 16 (3): 167\u2013186. doi: 10.1002/rmv.494",
                        "@reference-instance-id": "OB2BibRecID-949395379-36ca33f4dd37c41547ca9f3166d1cee3-22",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2006"},
                            "ref-title": {"ref-titletext": "Adenovirus: from foe to friend"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1002/rmv.494",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0022",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "33744982923",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "16",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "167",
                                    "@last": "186"
                                }
                            },
                            "ref-text": "May",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Goncalves",
                                    "ce:indexed-name": "Goncalves M.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.A.",
                                    "@_fa": "true",
                                    "ce:surname": "de Vries",
                                    "ce:indexed-name": "de Vries A.A."
                                }
                            ]},
                            "ref-sourcetitle": "Rev Med Virol"
                        },
                        "ce:source-text": "Goncalves MA, de Vries AA. Adenovirus: from foe to friend. Rev Med Virol. 2006 May; 16 (3): 167\u2013186. doi: 10.1002/rmv.494"
                    },
                    {
                        "ref-fulltext": "Vaxzevria, COVID-19 Vaccine (ChAdox1-S [recombinant]) SmPC.",
                        "@reference-instance-id": "OB2BibRecID-949395379-ccd4f3c7d78f3a79a296988c81fcd513-23",
                        "@id": "23",
                        "ref-info": {
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0023",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164473555",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Vaxzevria",
                                "ce:indexed-name": "Vaxzevria"
                            }},
                            "ref-sourcetitle": "COVID-19 Vaccine (ChAdox1-S [recombinant]) SmPC"
                        },
                        "ce:source-text": "Vaxzevria, COVID-19 Vaccine (ChAdox1-S [recombinant]) SmPC."
                    },
                    {
                        "ref-fulltext": "COVSHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine [Recombinant]) Fact Sheet.",
                        "@reference-instance-id": "OB2BibRecID-949395379-4dca005227aa942bbe6400765d168fb8-24",
                        "@id": "24",
                        "ref-info": {
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0024",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164515795",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "COVSHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine [Recombinant]) Fact Sheet",
                                "ce:indexed-name": "COVSHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine [Recombinant]) Fact Sheet"
                            }}
                        },
                        "ce:source-text": "COVSHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine [Recombinant]) Fact Sheet."
                    },
                    {
                        "ref-fulltext": "Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021 Dec 16; 385 (25): 2348\u20132360.",
                        "@reference-instance-id": "OB2BibRecID-949395379-db26a80e78ef831fff2ff00991294bbd-25",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCoV-19) Covid-19 vaccine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0025",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85122076939",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "385",
                                    "@issue": "25"
                                },
                                "pagerange": {
                                    "@first": "2348",
                                    "@last": "2360"
                                }
                            },
                            "ref-text": "Dec, 16",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Falsey",
                                        "ce:indexed-name": "Falsey A.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Sobieszczyk",
                                        "ce:indexed-name": "Sobieszczyk M.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirsch",
                                        "ce:indexed-name": "Hirsch I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021 Dec 16; 385 (25): 2348\u20132360."
                    },
                    {
                        "ref-fulltext": "Di Pasquale A, Preiss S, Tavares Da Silva F, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel). 2015 Apr 16; 3 (2): 320\u2013343.",
                        "@reference-instance-id": "OB2BibRecID-949395379-4c57d08167a2484b015c8d23c6457da6-26",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Vaccine adjuvants: from 1920 to 2015 and beyond"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0026",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85001019062",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "320",
                                    "@last": "343"
                                }
                            },
                            "ref-text": "Apr, 16",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Di Pasquale",
                                        "ce:indexed-name": "Di Pasquale A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Preiss",
                                        "ce:indexed-name": "Preiss S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Tavares Da Silva",
                                        "ce:indexed-name": "Tavares Da Silva F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Vaccines (Basel)"
                        },
                        "ce:source-text": "Di Pasquale A, Preiss S, Tavares Da Silva F, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel). 2015 Apr 16; 3 (2): 320\u2013343."
                    },
                    {
                        "ref-fulltext": "Marchese AM, Beyhaghi H, Orenstein WA. With established safe and effective use, protein vaccines offer another choice against COVID-19. Vaccine. 2022 Nov 2; 40 (46): 6567\u20136569.",
                        "@reference-instance-id": "OB2BibRecID-949395379-babfa7c9c1727191571c66db53354ec1-27",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "With established safe and effective use, protein vaccines offer another choice against COVID-19"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0027",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85139726150",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "40",
                                    "@issue": "46"
                                },
                                "pagerange": {
                                    "@first": "6567",
                                    "@last": "6569"
                                }
                            },
                            "ref-text": "Nov, 2",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Marchese",
                                    "ce:indexed-name": "Marchese A.M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Beyhaghi",
                                    "ce:indexed-name": "Beyhaghi H."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "W.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Orenstein",
                                    "ce:indexed-name": "Orenstein W.A."
                                }
                            ]},
                            "ref-sourcetitle": "Vaccine"
                        },
                        "ce:source-text": "Marchese AM, Beyhaghi H, Orenstein WA. With established safe and effective use, protein vaccines offer another choice against COVID-19. Vaccine. 2022 Nov 2; 40 (46): 6567\u20136569."
                    },
                    {
                        "ref-fulltext": "Stertman L, Palm AE, Zarnegar B, et al. The matrix-M adjuvant: a critical component of vaccines for the 21(st) century. Hum Vaccin Immunother. 2023 Dec 31; 19 (1): 2189885.",
                        "@reference-instance-id": "OB2BibRecID-949395379-c9d6c80f9b5174f2cced4ad080585487-28",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "The matrix-M adjuvant: a critical component of vaccines for the 21(st) century"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0028",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85158076957",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "19",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "2189885"}
                            },
                            "ref-text": "Dec, 31",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Stertman",
                                        "ce:indexed-name": "Stertman L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Palm",
                                        "ce:indexed-name": "Palm A.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Zarnegar",
                                        "ce:indexed-name": "Zarnegar B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Hum Vaccin Immunother"
                        },
                        "ce:source-text": "Stertman L, Palm AE, Zarnegar B, et al. The matrix-M adjuvant: a critical component of vaccines for the 21(st) century. Hum Vaccin Immunother. 2023 Dec 31; 19 (1): 2189885."
                    },
                    {
                        "ref-fulltext": "Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021 Sep 23; 385 (13): 1172\u20131183.",
                        "@reference-instance-id": "OB2BibRecID-949395379-139885399db421e2e52a3bc7b71b6ac8-29",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Safety and Efficacy of NVX-CoV2373 Covid-19 vaccine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0029",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85115756115",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "385",
                                    "@issue": "13"
                                },
                                "pagerange": {
                                    "@first": "1172",
                                    "@last": "1183"
                                }
                            },
                            "ref-text": "Sep, 23",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Heath",
                                        "ce:indexed-name": "Heath P.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Galiza",
                                        "ce:indexed-name": "Galiza E.P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Baxter",
                                        "ce:indexed-name": "Baxter D.N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021 Sep 23; 385 (13): 1172\u20131183."
                    },
                    {
                        "ref-fulltext": "VidPrevtyn Beta, COVID-19 Vaccine SmPC.",
                        "@reference-instance-id": "OB2BibRecID-949395379-feb18f00475c9089c4458ac1f0e8efb5-30",
                        "@id": "30",
                        "ref-info": {
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0030",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164518804",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "VidPrevtyn Beta",
                                "ce:indexed-name": "VidPrevtyn Beta"
                            }},
                            "ref-sourcetitle": "COVID-19 Vaccine SmPC"
                        },
                        "ce:source-text": "VidPrevtyn Beta, COVID-19 Vaccine SmPC."
                    },
                    {
                        "ref-fulltext": "Thuluva S, Paradkar V, Gunneri SR, et al. Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. EBioMedicine. 2022 Sep; 83: 104217.",
                        "@reference-instance-id": "OB2BibRecID-949395379-eb1e7bcfb68318334cfb846a11b6e859-31",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0031",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85135863511",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "83"},
                                "pagerange": {"@first": "104217"}
                            },
                            "ref-text": "Sep",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Thuluva",
                                        "ce:indexed-name": "Thuluva S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Paradkar",
                                        "ce:indexed-name": "Paradkar V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Gunneri",
                                        "ce:indexed-name": "Gunneri S.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "EBioMedicine"
                        },
                        "ce:source-text": "Thuluva S, Paradkar V, Gunneri SR, et al. Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. EBioMedicine. 2022 Sep; 83: 104217."
                    },
                    {
                        "ref-fulltext": "Gao L, Li Y, He P, et al. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. Lancet Child Adolesc Health. 2023 Apr; 7 (4): 269\u2013279.",
                        "@reference-instance-id": "OB2BibRecID-949395379-c3bd6e72f005cdff859e6806a7d8d830-32",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0032",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85149615805",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "269",
                                    "@last": "279"
                                }
                            },
                            "ref-text": "Apr",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Gao",
                                        "ce:indexed-name": "Gao L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "He",
                                        "ce:indexed-name": "He P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Child Adolesc Health"
                        },
                        "ce:source-text": "Gao L, Li Y, He P, et al. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. Lancet Child Adolesc Health. 2023 Apr; 7 (4): 269\u2013279."
                    },
                    {
                        "ref-fulltext": "Chakraborty C, Sharma AR, Bhattacharya M, et al. Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis. Vaccines (Basel). 2021 Jun 4; 9 (6): 600.",
                        "@reference-instance-id": "OB2BibRecID-949395379-4e61a12721c62bdce614db1a17f90adf-33",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0033",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85108210319",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "9",
                                    "@issue": "6"
                                },
                                "pagerange": {"@first": "600"}
                            },
                            "ref-text": "Jun, 4",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Chakraborty",
                                        "ce:indexed-name": "Chakraborty C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Sharma",
                                        "ce:indexed-name": "Sharma A.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Bhattacharya",
                                        "ce:indexed-name": "Bhattacharya M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Vaccines (Basel)"
                        },
                        "ce:source-text": "Chakraborty C, Sharma AR, Bhattacharya M, et al. Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis. Vaccines (Basel). 2021 Jun 4; 9 (6): 600."
                    },
                    {
                        "ref-fulltext": "Dolgin E. Omicron thwarts some of the world\u2019s most-used COVID vaccines. Nature. 2022 Jan; 601 (7893): 311. doi: 10.1038/d41586-022-00079-6",
                        "@reference-instance-id": "OB2BibRecID-949395379-56daa740a7cd7400172210c27364fb61-34",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Omicron thwarts some of the world\u2019s most-used COVID vaccines"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1038/d41586-022-00079-6",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0034",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85123566274",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "601",
                                    "@issue": "7893"
                                },
                                "pagerange": {"@first": "311"}
                            },
                            "ref-text": "Jan",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "E.",
                                "@_fa": "true",
                                "ce:surname": "Dolgin",
                                "ce:indexed-name": "Dolgin E."
                            }]},
                            "ref-sourcetitle": "Nature"
                        },
                        "ce:source-text": "Dolgin E. Omicron thwarts some of the world\u2019s most-used COVID vaccines. Nature. 2022 Jan; 601 (7893): 311. doi: 10.1038/d41586-022-00079-6"
                    },
                    {
                        "ref-fulltext": "Pettersson H, Manley B, Hernandez S, et al. Tracking COVID-19 vaccinations worldwide: cNN Health [updated 2023 Mar20; cited 2023 Apr27]. Available from: https://edition.cnn.com/interactive/2021/health/global-covid-vaccinations/",
                        "@reference-instance-id": "OB2BibRecID-949395379-23d4bf3ee0b2e08da5635c1ca81fb205-35",
                        "@id": "35",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://edition.cnn.com/interactive/2021/health/global-covid-vaccinations/",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0035",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85114598808",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "updated 2023 Mar20; cited 2023 Apr27, Available from",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Pettersson",
                                        "ce:indexed-name": "Pettersson H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Manley",
                                        "ce:indexed-name": "Manley B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Hernandez",
                                        "ce:indexed-name": "Hernandez S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Tracking COVID-19 vaccinations worldwide: cNN Health"
                        },
                        "ce:source-text": "Pettersson H, Manley B, Hernandez S, et al. Tracking COVID-19 vaccinations worldwide: cNN Health [updated 2023 Mar20; cited 2023 Apr27]. Available from: https://edition.cnn.com/interactive/2021/health/global-covid-vaccinations/"
                    },
                    {
                        "ref-fulltext": "Holder J Tracking Coronavirus Vaccinations Around the World. The New York Times; [updated 2023 Mar13; cited 2023 Apr27]. Available from: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html",
                        "@reference-instance-id": "OB2BibRecID-949395379-e8a0866da0d658f9d6bfa3f44a959512-36",
                        "@id": "36",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Tracking Coronavirus Vaccinations Around the World"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0036",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85104435130",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "[updated 2023 Mar13, cited 2023 Apr27], Available from",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "J.",
                                "@_fa": "true",
                                "ce:surname": "Holder",
                                "ce:indexed-name": "Holder J."
                            }]},
                            "ref-sourcetitle": "The New York Times;"
                        },
                        "ce:source-text": "Holder J Tracking Coronavirus Vaccinations Around the World. The New York Times; [updated 2023 Mar13; cited 2023 Apr27]. Available from: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html"
                    },
                    {
                        "ref-fulltext": "Which COVID-19 vaccine is the most widely accepted for international travel? The Economist [updated 2021 Jul20; cited 2023 Apr27]. Available from: https://www.economist.com/graphic-detail/2021/07/20/which-covid-19-vaccine-is-the-most-widely-accepted-for-international-travel",
                        "@reference-instance-id": "OB2BibRecID-949395379-4e2ca29b5a32d1bb2fac994a0433b42c-37",
                        "@id": "37",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.economist.com/graphic-detail/2021/07/20/which-covid-19-vaccine-is-the-most-widely-accepted-for-international-travel",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0037",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "77952311184",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "[updated 2021 Jul20, cited 2023 Apr27], Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Which COVID-19 vaccine is the most widely accepted for international travel?",
                                "ce:indexed-name": "Which COVID-19 vaccine is the most widely accepted for international travel?"
                            }},
                            "ref-sourcetitle": "The Economist"
                        },
                        "ce:source-text": "Which COVID-19 vaccine is the most widely accepted for international travel? The Economist [updated 2021 Jul20; cited 2023 Apr27]. Available from: https://www.economist.com/graphic-detail/2021/07/20/which-covid-19-vaccine-is-the-most-widely-accepted-for-international-travel"
                    },
                    {
                        "ref-fulltext": "Ministry of Health and Family Welfare. Co-win: winning over Covid-19 [cited 2023 Apr27]. Available from: https://dashboard.cowin.gov.in/",
                        "@reference-instance-id": "OB2BibRecID-949395379-65e4040954e24bbb8869d3e4b9a072cb-38",
                        "@id": "38",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://dashboard.cowin.gov.in/",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0038",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85135361164",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "[cited 2023 Apr27], Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Ministry of Health and Family Welfare",
                                "ce:indexed-name": "Ministry of Health and Family Welfare"
                            }},
                            "ref-sourcetitle": "Co-win: winning over Covid-19"
                        },
                        "ce:source-text": "Ministry of Health and Family Welfare. Co-win: winning over Covid-19 [cited 2023 Apr27]. Available from: https://dashboard.cowin.gov.in/"
                    },
                    {
                        "ref-fulltext": "Toback S, Marchese AM, Warren B, et al. Safety and Immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine: an interim analysis. medRxiv. 2023; Preprint:. doi: 10.1101/2023.03.24.23287658.",
                        "@reference-instance-id": "OB2BibRecID-949395379-a2a9b8e05c0781e982ed4644c3e35028-39",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "Safety and Immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine: an interim analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1101/2023.03.24.23287658",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0039",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164503111",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Preprint",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Toback",
                                        "ce:indexed-name": "Toback S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Marchese",
                                        "ce:indexed-name": "Marchese A.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Warren",
                                        "ce:indexed-name": "Warren B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "medRxiv"
                        },
                        "ce:source-text": "Toback S, Marchese AM, Warren B, et al. Safety and Immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine: an interim analysis. medRxiv. 2023; Preprint:. doi: 10.1101/2023.03.24.23287658."
                    },
                    {
                        "ref-fulltext": "Kulkarni P, Gunale B, Kohli S, et al. A randomized, controlled study to evaluate the safety and immunogenicity of a heterologous booster dose of an adjuvanted SARS CoV-2 recombinant spike protein vaccine in adults. Res Square. 2023; Preprint. doi: 10.21203/rs.3.rs-2549560/v1.",
                        "@reference-instance-id": "OB2BibRecID-949395379-9de36d27b7b920f2944d310cec100062-40",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "A randomized, controlled study to evaluate the safety and immunogenicity of a heterologous booster dose of an adjuvanted SARS CoV-2 recombinant spike protein vaccine in adults"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.21203/rs.3.rs-2549560/v1",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0040",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164491052",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Preprint",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Kulkarni",
                                        "ce:indexed-name": "Kulkarni P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Gunale",
                                        "ce:indexed-name": "Gunale B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kohli",
                                        "ce:indexed-name": "Kohli S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Res Square"
                        },
                        "ce:source-text": "Kulkarni P, Gunale B, Kohli S, et al. A randomized, controlled study to evaluate the safety and immunogenicity of a heterologous booster dose of an adjuvanted SARS CoV-2 recombinant spike protein vaccine in adults. Res Square. 2023; Preprint. doi: 10.21203/rs.3.rs-2549560/v1."
                    },
                    {
                        "ref-fulltext": "Kanokudom S, Chansaenroj J, Suntronwong N, et al. Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(tm)) after homologous and heterologous two-dose regimens. Int J Infect Dis. 2023 Jan; 126: 64\u201372. doi: 10.1016/j.ijid.2022.11.022.",
                        "@reference-instance-id": "OB2BibRecID-949395379-8801e106ef3f1fbb29af1f2724f6254f-41",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(tm)) after homologous and heterologous two-dose regimens"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/j.ijid.2022.11.022",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0041",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85143497788",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "126"},
                                "pagerange": {
                                    "@first": "64",
                                    "@last": "72"
                                }
                            },
                            "ref-text": "Jan",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kanokudom",
                                        "ce:indexed-name": "Kanokudom S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Chansaenroj",
                                        "ce:indexed-name": "Chansaenroj J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Suntronwong",
                                        "ce:indexed-name": "Suntronwong N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Int J Infect Dis"
                        },
                        "ce:source-text": "Kanokudom S, Chansaenroj J, Suntronwong N, et al. Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(tm)) after homologous and heterologous two-dose regimens. Int J Infect Dis. 2023 Jan; 126: 64\u201372. doi: 10.1016/j.ijid.2022.11.022."
                    },
                    {
                        "ref-fulltext": "Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18; 398 (10318): 2258\u20132276. doi: 10.1016/S0140-6736(21)02717-3.",
                        "@reference-instance-id": "OB2BibRecID-949395379-51155937d6837fc5e97c391375017353-42",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/S0140-6736(21)02717-3",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0042",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85121237638",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "398"},
                                "pagerange": {
                                    "@first": "2258",
                                    "@last": "2276"
                                }
                            },
                            "ref-text": "Dec, 18, 10318",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.P.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Munro",
                                        "ce:indexed-name": "Munro A.P.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Janani",
                                        "ce:indexed-name": "Janani L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Cornelius",
                                        "ce:indexed-name": "Cornelius V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18; 398 (10318): 2258\u20132276. doi: 10.1016/S0140-6736(21)02717-3."
                    },
                    {
                        "ref-fulltext": "Liu X, Munro APS, Wright A, et al. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. J Infect. 2023 Apr 19; 87 (1): 18\u201326. doi: 10.1016/j.jinf.2023.04.012.",
                        "@reference-instance-id": "OB2BibRecID-949395379-2207559231f7be3b4a68f654d2ce0e74-43",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/j.jinf.2023.04.012",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0043",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85160326172",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "87",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "18",
                                    "@last": "26"
                                }
                            },
                            "ref-text": "Apr, 19",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu X."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.P.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Munro",
                                        "ce:indexed-name": "Munro A.P.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Wright",
                                        "ce:indexed-name": "Wright A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Infect"
                        },
                        "ce:source-text": "Liu X, Munro APS, Wright A, et al. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. J Infect. 2023 Apr 19; 87 (1): 18\u201326. doi: 10.1016/j.jinf.2023.04.012."
                    },
                    {
                        "ref-fulltext": "Assawakosri S, Kanokudom S, Chansaenroj J, et al. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. Int J Infect Dis. 2022 Sep; 122: 793\u2013801.",
                        "@reference-instance-id": "OB2BibRecID-949395379-508261f8aa9a140078cac545e61de902-44",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0044",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85135271939",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "122"},
                                "pagerange": {
                                    "@first": "793",
                                    "@last": "801"
                                }
                            },
                            "ref-text": "Sep",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Assawakosri",
                                        "ce:indexed-name": "Assawakosri S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kanokudom",
                                        "ce:indexed-name": "Kanokudom S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Chansaenroj",
                                        "ce:indexed-name": "Chansaenroj J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Int J Infect Dis"
                        },
                        "ce:source-text": "Assawakosri S, Kanokudom S, Chansaenroj J, et al. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. Int J Infect Dis. 2022 Sep; 122: 793\u2013801."
                    },
                    {
                        "ref-fulltext": "Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022 Nov; 22 (11): 1565\u20131576.",
                        "@reference-instance-id": "OB2BibRecID-949395379-e1d5db257a1e6c495bbf970177d251a6-45",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0045",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136610740",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "22",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "1565",
                                    "@last": "1576"
                                }
                            },
                            "ref-text": "Nov",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Mallory",
                                        "ce:indexed-name": "Mallory R.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Formica",
                                        "ce:indexed-name": "Formica N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Pfeiffer",
                                        "ce:indexed-name": "Pfeiffer S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Infect Dis"
                        },
                        "ce:source-text": "Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022 Nov; 22 (11): 1565\u20131576."
                    },
                    {
                        "ref-fulltext": "Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31; 383 (27): 2603\u20132615.",
                        "@reference-instance-id": "OB2BibRecID-949395379-21d7316082f43c4e8cd1df63e49a9598-46",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0046",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85098117107",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "383",
                                    "@issue": "27"
                                },
                                "pagerange": {
                                    "@first": "2603",
                                    "@last": "2615"
                                }
                            },
                            "ref-text": "Dec, 31",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Polack",
                                        "ce:indexed-name": "Polack F.P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Thomas",
                                        "ce:indexed-name": "Thomas S.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Kitchin",
                                        "ce:indexed-name": "Kitchin N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31; 383 (27): 2603\u20132615."
                    },
                    {
                        "ref-fulltext": "Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4; 384 (5): 403\u2013416.",
                        "@reference-instance-id": "OB2BibRecID-949395379-93710a642672080f9f0386ad53179e07-47",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0047",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85100821483",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "384",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "403",
                                    "@last": "416"
                                }
                            },
                            "ref-text": "Feb, 4",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Baden",
                                        "ce:indexed-name": "Baden L.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.M.",
                                        "@_fa": "true",
                                        "ce:surname": "El Sahly",
                                        "ce:indexed-name": "El Sahly H.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Essink",
                                        "ce:indexed-name": "Essink B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4; 384 (5): 403\u2013416."
                    },
                    {
                        "ref-fulltext": "Garg I, Sheikh AB, Pal S, et al. Mix-and-match COVID-19 vaccinations (heterologous boost): a review. Infect Dis Rep. 2022 Jul20; 14 (4): 537\u2013546. doi: 10.3390/idr14040057",
                        "@reference-instance-id": "OB2BibRecID-949395379-445e5ac8dbbe075824b077159a97db31-48",
                        "@id": "48",
                        "ref-info": {
                            "ref-title": {"ref-titletext": "Mix-and-match COVID-19 vaccinations (heterologous boost): a review"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.3390/idr14040057",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0048",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136681571",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "14",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "537",
                                    "@last": "546"
                                }
                            },
                            "ref-text": "2022 Jul20",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Garg",
                                        "ce:indexed-name": "Garg I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Sheikh",
                                        "ce:indexed-name": "Sheikh A.B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Pal",
                                        "ce:indexed-name": "Pal S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Infect Dis Rep"
                        },
                        "ce:source-text": "Garg I, Sheikh AB, Pal S, et al. Mix-and-match COVID-19 vaccinations (heterologous boost): a review. Infect Dis Rep. 2022 Jul20; 14 (4): 537\u2013546. doi: 10.3390/idr14040057"
                    },
                    {
                        "ref-fulltext": "Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022 Mar 17; 386 (11): 1046\u20131057.",
                        "@reference-instance-id": "OB2BibRecID-949395379-a04c32c151ddf7ff3f510b0f6af290bc-49",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Homologous and heterologous Covid-19 booster vaccinations"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0049",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85125117516",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "386",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "1046",
                                    "@last": "1057"
                                }
                            },
                            "ref-text": "Mar, 17",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Atmar",
                                        "ce:indexed-name": "Atmar R.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Lyke",
                                        "ce:indexed-name": "Lyke K.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Deming",
                                        "ce:indexed-name": "Deming M.E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022 Mar 17; 386 (11): 1046\u20131057."
                    },
                    {
                        "ref-fulltext": "Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 Sep; 27 (9): 1525\u20131529.",
                        "@reference-instance-id": "OB2BibRecID-949395379-70ff1d4af4a29a7ef3e78f84d9a38816-50",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0050",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111083355",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "1525",
                                    "@last": "1529"
                                }
                            },
                            "ref-text": "Sep",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Barros-Martins",
                                        "ce:indexed-name": "Barros-Martins J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Hammerschmidt",
                                        "ce:indexed-name": "Hammerschmidt S.I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Cossmann",
                                        "ce:indexed-name": "Cossmann A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 Sep; 27 (9): 1525\u20131529."
                    },
                    {
                        "ref-fulltext": "Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021 Sep; 27 (9): 1530\u20131535.",
                        "@reference-instance-id": "OB2BibRecID-949395379-4fbcc5659e8c73f213c94f4d2dcd5f00-51",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0051",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111656735",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "1530",
                                    "@last": "1535"
                                }
                            },
                            "ref-text": "Sep",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Schmidt",
                                        "ce:indexed-name": "Schmidt T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Klemis",
                                        "ce:indexed-name": "Klemis V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Schub",
                                        "ce:indexed-name": "Schub D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021 Sep; 27 (9): 1530\u20131535."
                    },
                    {
                        "ref-fulltext": "Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 Sep 4; 398 (10303): 856\u2013869.",
                        "@reference-instance-id": "OB2BibRecID-949395379-92711bf0f618c68f2430a47dfaa150e5-52",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0052",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85114018548",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "398"},
                                "pagerange": {
                                    "@first": "856",
                                    "@last": "869"
                                }
                            },
                            "ref-text": "Sep, 4, 10303",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu X."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Shaw",
                                        "ce:indexed-name": "Shaw R.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.S.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Stuart",
                                        "ce:indexed-name": "Stuart A.S.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 Sep 4; 398 (10303): 856\u2013869."
                    },
                    {
                        "ref-fulltext": "Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021 Dec; 600 (7890): 701\u2013706.",
                        "@reference-instance-id": "OB2BibRecID-949395379-7b778ee12e5864d8238e701ca6203bb6-53",
                        "@id": "53",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0053",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85118176291",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "600",
                                    "@issue": "7890"
                                },
                                "pagerange": {
                                    "@first": "701",
                                    "@last": "706"
                                }
                            },
                            "ref-text": "Dec",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Pozzetto",
                                        "ce:indexed-name": "Pozzetto B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Legros",
                                        "ce:indexed-name": "Legros V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Djebali",
                                        "ce:indexed-name": "Djebali S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nature"
                        },
                        "ce:source-text": "Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021 Dec; 600 (7890): 701\u2013706."
                    },
                    {
                        "ref-fulltext": "Tan CS, Collier AY, Yu J, et al. Durability of Heterologous and homologous COVID-19 vaccine boosts. JAMA Netw Open. 2022 Aug 1; 5 (8): e2226335.",
                        "@reference-instance-id": "OB2BibRecID-949395379-249233f34f1f5b1635c8b5f788f0c5cb-54",
                        "@id": "54",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Durability of Heterologous and homologous COVID-19 vaccine boosts"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0054",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136339376",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "8"
                                },
                                "pagerange": {"@first": "e2226335"}
                            },
                            "ref-text": "Aug, 1",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tan",
                                        "ce:indexed-name": "Tan C.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Collier",
                                        "ce:indexed-name": "Collier A.Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Yu",
                                        "ce:indexed-name": "Yu J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Netw Open"
                        },
                        "ce:source-text": "Tan CS, Collier AY, Yu J, et al. Durability of Heterologous and homologous COVID-19 vaccine boosts. JAMA Netw Open. 2022 Aug 1; 5 (8): e2226335."
                    },
                    {
                        "ref-fulltext": "Assawakosri S, Kanokudom S, Suntronwong N, et al. Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of coronavac vaccination. J Infect Dis. 2022 Oct 17; 226 (8): 1372\u20131381.",
                        "@reference-instance-id": "OB2BibRecID-949395379-9fed352a4e7de76b34e0e9caf84183ec-55",
                        "@id": "55",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of coronavac vaccination"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0055",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85139343905",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "226",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "1372",
                                    "@last": "1381"
                                }
                            },
                            "ref-text": "Oct, 17",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Assawakosri",
                                        "ce:indexed-name": "Assawakosri S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kanokudom",
                                        "ce:indexed-name": "Kanokudom S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Suntronwong",
                                        "ce:indexed-name": "Suntronwong N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Infect Dis"
                        },
                        "ce:source-text": "Assawakosri S, Kanokudom S, Suntronwong N, et al. Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of coronavac vaccination. J Infect Dis. 2022 Oct 17; 226 (8): 1372\u20131381."
                    },
                    {
                        "ref-fulltext": "Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting, Zoom video conference [transcript]. 2023 Jan26. Accessed 26Jan 2023. Available from: https://www.fda.gov/media/165307/download",
                        "@reference-instance-id": "OB2BibRecID-949395379-cf9febbc29bd2bcf7f0c3490da4f0cae-56",
                        "@id": "56",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.fda.gov/media/165307/download",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Vaccines and Related Biological Products Advisory Committee (VRBPAC)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0056",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164454378",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "2023 Jan26, Accessed 26Jan 2023, Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Food and Drug Administration",
                                "ce:indexed-name": "Food and Drug Administration"
                            }},
                            "ref-sourcetitle": "Meeting, Zoom video conference [transcript"
                        },
                        "ce:source-text": "Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting, Zoom video conference [transcript]. 2023 Jan26. Accessed 26Jan 2023. Available from: https://www.fda.gov/media/165307/download"
                    },
                    {
                        "ref-fulltext": "Raiser F, Davis M, Adelglass J, et al. Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: a phase 3 randomized clinical trial in adults. medRxiv. 2023. Preprint. doi: 10.1101/2023.03.16.23287030.",
                        "@reference-instance-id": "OB2BibRecID-949395379-ed8b625130680ab12b5e67577586ae38-57",
                        "@id": "57",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: a phase 3 randomized clinical trial in adults"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1101/2023.03.16.23287030",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "cit0057",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164458229",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Preprint",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Raiser",
                                        "ce:indexed-name": "Raiser F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Davis",
                                        "ce:indexed-name": "Davis M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Adelglass",
                                        "ce:indexed-name": "Adelglass J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "medRxiv"
                        },
                        "ce:source-text": "Raiser F, Davis M, Adelglass J, et al. Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: a phase 3 randomized clinical trial in adults. medRxiv. 2023. Preprint. doi: 10.1101/2023.03.16.23287030."
                    },
                    {
                        "ref-fulltext": "Rubin R. COVID-19 vaccine makers plan for annual boosters, but it\u2019s not clear they\u2019ll be needed. JAMA. 2021 Dec 14; 326 (22): 2247\u20132249.",
                        "@reference-instance-id": "OB2BibRecID-949395379-d0525f2622e8c0e660eba31ff80d49e3-58",
                        "@id": "58",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "COVID-19 vaccine makers plan for annual boosters, but it\u2019s not clear they\u2019ll be needed"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0058",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85120345023",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "326",
                                    "@issue": "22"
                                },
                                "pagerange": {
                                    "@first": "2247",
                                    "@last": "2249"
                                }
                            },
                            "ref-text": "Dec, 14",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "R.",
                                "@_fa": "true",
                                "ce:surname": "Rubin",
                                "ce:indexed-name": "Rubin R."
                            }]},
                            "ref-sourcetitle": "JAMA"
                        },
                        "ce:source-text": "Rubin R. COVID-19 vaccine makers plan for annual boosters, but it\u2019s not clear they\u2019ll be needed. JAMA. 2021 Dec 14; 326 (22): 2247\u20132249."
                    },
                    {
                        "ref-fulltext": "Bergen N, Kirkby K, Fuertes CV, et al. Global state of education-related inequality in COVID-19 vaccine coverage, structural barriers, vaccine hesitancy, and vaccine refusal: findings from the Global COVID-19 Trends and Impact Survey. Lancet Glob Health. 2023 Feb; 11 (2): e207\u2013e217.",
                        "@reference-instance-id": "OB2BibRecID-949395379-45cdab94d0a916188af8204968e8c17e-59",
                        "@id": "59",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-title": {"ref-titletext": "Global state of education-related inequality in COVID-19 vaccine coverage, structural barriers, vaccine hesitancy, and vaccine refusal: findings from the Global COVID-19 Trends and Impact Survey"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0059",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85146346450",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "11",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "e207",
                                    "@last": "e217"
                                }
                            },
                            "ref-text": "Feb",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Bergen",
                                        "ce:indexed-name": "Bergen N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Kirkby",
                                        "ce:indexed-name": "Kirkby K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Fuertes",
                                        "ce:indexed-name": "Fuertes C.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Glob Health"
                        },
                        "ce:source-text": "Bergen N, Kirkby K, Fuertes CV, et al. Global state of education-related inequality in COVID-19 vaccine coverage, structural barriers, vaccine hesitancy, and vaccine refusal: findings from the Global COVID-19 Trends and Impact Survey. Lancet Glob Health. 2023 Feb; 11 (2): e207\u2013e217."
                    },
                    {
                        "ref-fulltext": "Beleche T, Ross T, Marus J, et al. COVID-19 vaccine hesitancy and reasons for hesitancy among essential and non-essential workers. 2023 March. Accessed 30June. Available from: https://aspe.hhs.gov/sites/default/files/documents/f2fbfbd9cdce16032233b6a9ff69f161/aspe-essential-worker-vaccine-hesitancy.pdf",
                        "@reference-instance-id": "OB2BibRecID-949395379-5e2ab25c4c3cbe3e567cca457407bd18-60",
                        "@id": "60",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2023"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://aspe.hhs.gov/sites/default/files/documents/f2fbfbd9cdce16032233b6a9ff69f161/aspe-essential-worker-vaccine-hesitancy.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0060",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164492662",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "March, Accessed 30June, Available from",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Beleche",
                                        "ce:indexed-name": "Beleche T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Ross",
                                        "ce:indexed-name": "Ross T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Marus",
                                        "ce:indexed-name": "Marus J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "COVID-19 vaccine hesitancy and reasons for hesitancy among essential and non-essential workers"
                        },
                        "ce:source-text": "Beleche T, Ross T, Marus J, et al. COVID-19 vaccine hesitancy and reasons for hesitancy among essential and non-essential workers. 2023 March. Accessed 30June. Available from: https://aspe.hhs.gov/sites/default/files/documents/f2fbfbd9cdce16032233b6a9ff69f161/aspe-essential-worker-vaccine-hesitancy.pdf"
                    },
                    {
                        "ref-fulltext": "Chrissian AA, Oyoyo UE, Patel P, et al. Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination. Vaccine. 2022 May 20; 40 (23): 3174\u20133181.",
                        "@reference-instance-id": "OB2BibRecID-949395379-6b1fe73316d9119f60545acf7c8b6b3c-61",
                        "@id": "61",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0061",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85130001160",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "40",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "3174",
                                    "@last": "3181"
                                }
                            },
                            "ref-text": "May, 20",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Chrissian",
                                        "ce:indexed-name": "Chrissian A.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "U.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Oyoyo",
                                        "ce:indexed-name": "Oyoyo U.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Patel",
                                        "ce:indexed-name": "Patel P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Vaccine"
                        },
                        "ce:source-text": "Chrissian AA, Oyoyo UE, Patel P, et al. Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination. Vaccine. 2022 May 20; 40 (23): 3174\u20133181."
                    },
                    {
                        "ref-fulltext": "Costa K Older adults\u2019 intentions and attitudes toward the updated bivalent COVID-19 booster: survey, United States, may 2023 HealthCanal2023 [cited 2023 May8]. Available from: https://www.healthcanal.com/health/the-bivalent-covid-19-booster-survey",
                        "@reference-instance-id": "OB2BibRecID-949395379-901409b78f0d31b1c3ea75eaaa696d71-62",
                        "@id": "62",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.healthcanal.com/health/the-bivalent-covid-19-booster-survey",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0062",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85164468224",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "[cited 2023 May8], Available from",
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "K.",
                                "@_fa": "true",
                                "ce:surname": "Costa",
                                "ce:indexed-name": "Costa K."
                            }]},
                            "ref-sourcetitle": "Older adults\u2019 intentions and attitudes toward the updated bivalent COVID-19 booster: survey, United States, may 2023 HealthCanal2023"
                        },
                        "ce:source-text": "Costa K Older adults\u2019 intentions and attitudes toward the updated bivalent COVID-19 booster: survey, United States, may 2023 HealthCanal2023 [cited 2023 May8]. Available from: https://www.healthcanal.com/health/the-bivalent-covid-19-booster-survey"
                    },
                    {
                        "ref-fulltext": "Sutton N, San Francisco Ramos A, Beales E, et al. Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. Expert Rev Vaccines. 2022 Sep; 21 (9): 1301\u20131318.",
                        "@reference-instance-id": "OB2BibRecID-949395379-3ac9bce11c9f379f4147bb6e4f5d72af-63",
                        "@id": "63",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "cit0063",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85134181413",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "21",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "1301",
                                    "@last": "1318"
                                }
                            },
                            "ref-text": "Sep",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Sutton",
                                        "ce:indexed-name": "Sutton N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "San Francisco Ramos",
                                        "ce:indexed-name": "San Francisco Ramos A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Beales",
                                        "ce:indexed-name": "Beales E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Expert Rev Vaccines"
                        },
                        "ce:source-text": "Sutton N, San Francisco Ramos A, Beales E, et al. Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. Expert Rev Vaccines. 2022 Sep; 21 (9): 1301\u20131318."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Gaithersburg",
            "@id": "60138508",
            "affilname": "Novavax, Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138508",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85164270417",
        "dc:description": "Introduction: Approximately half of the 13.4 billion COVID-19 vaccine doses administered globally were inactivated or viral vector platforms. The harmonization and optimization of vaccine regimens has become a key focus of policymakers and health-care providers and presents an opportunity to reassess the continued use of pandemic-era vaccines. Areas covered: Immunological evidence from studies of various homologous and heterologous regimens has been rapidly published; however, interpretation of these data is complicated by the many vaccine types and highly variable participant viral exposure and vaccination histories. Recent studies demonstrate that after primary series doses of inactivated (i.e. BBV152, and BBIBP-CorV), and viral vector (ChAdOx1 nCov-2019) vaccines, a heterologous boost with protein-based NVX-CoV2373 elicits more potent ancestral strain and omicron-specific antibody responses compared to homologous and heterologous inactivated and viral vector boosts. Expert opinion: While mRNA vaccines likely yield similar performance to protein-based heterologous booster doses, the latter offers notable advantages to countries with high uptake of inactivated and viral vector vaccines in terms of transportation and storage logistics and can potentially appeal to vaccine hesitant individuals. Moving forward, vaccine-mediated protection in inactivated and viral vector recipients may be optimized with the use of a heterologous protein-based booster such as NVX-CoV2373. Pivoting to Protein: The Immunogenicity and Safety of Protein-based NVX-CoV2373 as a Heterologous Booster for Inactivated and Viral Vector COVID-19 Vaccines. Inactivated or viral vector primary series following a booster dose with homologous or heterologous inactivated vaccines (i.e., BBV152, BBIBP-CorV), and homologous or heterologous viral vector vaccines (i.e., ChAd-Ox1 nCov-19) induces suboptimal immunogenicity compared to the enhanced immunogenicity of heterologous protein-based vaccine NVX-CoV2373.",
        "pubmed-id": "37386785",
        "prism:coverDate": "2023-01-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85164270417",
        "dc:creator": {"author": [{
            "ce:given-name": "Anthony M.",
            "preferred-name": {
                "ce:given-name": "Anthony M.",
                "ce:initials": "A.M.",
                "ce:surname": "Marchese",
                "ce:indexed-name": "Marchese A.M."
            },
            "@seq": "1",
            "ce:initials": "A.M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60138508",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138508"
            },
            "ce:surname": "Marchese",
            "@auid": "57925281800",
            "author-url": "https://api.elsevier.com/content/author/author_id/57925281800",
            "ce:indexed-name": "Marchese A.M."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85164270417"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85164270417&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85164270417&origin=inward"
            }
        ],
        "source-id": "20783",
        "citedby-count": "0",
        "prism:volume": "22",
        "subtype": "no",
        "dc:title": "Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines",
        "openaccess": "1",
        "prism:issn": "17448395 14760584",
        "publishercopyright": "© 2023 Novavax Inc. Published by Informa UK Limited, trading as Taylor & Francis Group.",
        "prism:issueIdentifier": "1",
        "subtypeDescription": "Note",
        "prism:publicationName": "Expert Review of Vaccines",
        "prism:pageRange": "620-628",
        "prism:endingPage": "628",
        "openaccessFlag": "true",
        "prism:doi": "10.1080/14760584.2023.2232020",
        "prism:startingPage": "620",
        "dc:identifier": "SCOPUS_ID:85164270417",
        "dc:publisher": "Taylor and Francis Ltd."
    },
    "idxterms": {"mainterm": [
        {
            "$": "Antibodies, Viral",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "COVID-19",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "COVID-19 Vaccines",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Immunogenicity, Vaccine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "SARS-CoV-2",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Vaccines, Inactivated",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Viral Vaccines",
            "@weight": "a",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "COVID-19 vaccines"
        },
        {
            "@_fa": "true",
            "$": "heterologous booster"
        },
        {
            "@_fa": "true",
            "$": "inactivated"
        },
        {
            "@_fa": "true",
            "$": "NVX-CoV2373"
        },
        {
            "@_fa": "true",
            "$": "protein-based"
        },
        {
            "@_fa": "true",
            "$": "viral vector"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Anthony M.",
            "preferred-name": {
                "ce:given-name": "Anthony M.",
                "ce:initials": "A.M.",
                "ce:surname": "Marchese",
                "ce:indexed-name": "Marchese A.M."
            },
            "@seq": "1",
            "ce:initials": "A.M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60138508",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138508"
            },
            "ce:surname": "Marchese",
            "@auid": "57925281800",
            "author-url": "https://api.elsevier.com/content/author/author_id/57925281800",
            "ce:indexed-name": "Marchese A.M."
        },
        {
            "ce:given-name": "Raj",
            "preferred-name": {
                "ce:given-name": "Raj",
                "ce:initials": "R.",
                "ce:surname": "Kalkeri",
                "ce:indexed-name": "Kalkeri R."
            },
            "@seq": "2",
            "ce:initials": "R.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60138508",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138508"
            },
            "ce:surname": "Kalkeri",
            "@auid": "57191375845",
            "author-url": "https://api.elsevier.com/content/author/author_id/57191375845",
            "ce:indexed-name": "Kalkeri R."
        },
        {
            "ce:given-name": "Muruga",
            "preferred-name": {
                "ce:given-name": "Muruga",
                "ce:initials": "M.",
                "ce:surname": "Vadivale",
                "ce:indexed-name": "Vadivale M."
            },
            "@seq": "3",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60138508",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138508"
            },
            "ce:surname": "Vadivale",
            "@auid": "6507179068",
            "author-url": "https://api.elsevier.com/content/author/author_id/6507179068",
            "ce:indexed-name": "Vadivale M."
        },
        {
            "ce:given-name": "Nungruthai",
            "preferred-name": {
                "ce:given-name": "Nungruthai",
                "ce:initials": "N.",
                "ce:surname": "Suntronwong",
                "ce:indexed-name": "Suntronwong N."
            },
            "@seq": "4",
            "ce:initials": "N.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Suntronwong",
            "@auid": "57189067135",
            "author-url": "https://api.elsevier.com/content/author/author_id/57189067135",
            "ce:indexed-name": "Suntronwong N."
        },
        {
            "ce:given-name": "Seth",
            "preferred-name": {
                "ce:given-name": "Seth",
                "ce:initials": "S.",
                "ce:surname": "Toback",
                "ce:indexed-name": "Toback S."
            },
            "@seq": "5",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60138508",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138508"
            },
            "ce:surname": "Toback",
            "@auid": "14032330900",
            "author-url": "https://api.elsevier.com/content/author/author_id/14032330900",
            "ce:indexed-name": "Toback S."
        },
        {
            "ce:given-name": "Yong",
            "preferred-name": {
                "ce:given-name": "Yong",
                "ce:initials": "Y.",
                "ce:surname": "Poovorawan",
                "ce:indexed-name": "Poovorawan Y."
            },
            "@seq": "6",
            "ce:initials": "Y.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Poovorawan",
            "@auid": "7102786191",
            "author-url": "https://api.elsevier.com/content/author/author_id/7102786191",
            "ce:indexed-name": "Poovorawan Y."
        }
    ]}
}}